CN106061984A - 前药化合物及其用途 - Google Patents

前药化合物及其用途 Download PDF

Info

Publication number
CN106061984A
CN106061984A CN201580008367.0A CN201580008367A CN106061984A CN 106061984 A CN106061984 A CN 106061984A CN 201580008367 A CN201580008367 A CN 201580008367A CN 106061984 A CN106061984 A CN 106061984A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
heteroalkyl
compound
biological agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580008367.0A
Other languages
English (en)
Chinese (zh)
Inventor
L·智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Priority to CN202210110476.5A priority Critical patent/CN114404427A/zh
Publication of CN106061984A publication Critical patent/CN106061984A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/098—Esters of polyphosphoric acids or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657154—Cyclic esteramides of oxyacids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580008367.0A 2014-02-13 2015-02-11 前药化合物及其用途 Pending CN106061984A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210110476.5A CN114404427A (zh) 2014-02-13 2015-02-11 前药化合物及其用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461939615P 2014-02-13 2014-02-13
US61/939,615 2014-02-13
US201461988101P 2014-05-02 2014-05-02
US201461988118P 2014-05-02 2014-05-02
US61/988,101 2014-05-02
US61/988,118 2014-05-02
PCT/US2015/015496 WO2015123352A1 (en) 2014-02-13 2015-02-11 Prodrug compounds and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210110476.5A Division CN114404427A (zh) 2014-02-13 2015-02-11 前药化合物及其用途

Publications (1)

Publication Number Publication Date
CN106061984A true CN106061984A (zh) 2016-10-26

Family

ID=53800601

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580008367.0A Pending CN106061984A (zh) 2014-02-13 2015-02-11 前药化合物及其用途
CN202210110476.5A Pending CN114404427A (zh) 2014-02-13 2015-02-11 前药化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210110476.5A Pending CN114404427A (zh) 2014-02-13 2015-02-11 前药化合物及其用途

Country Status (7)

Country Link
US (2) US10449210B2 (https=)
EP (2) EP3105238A4 (https=)
JP (3) JP2017512183A (https=)
CN (2) CN106061984A (https=)
AU (3) AU2015217221A1 (https=)
CA (1) CA2937548C (https=)
WO (1) WO2015123352A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129827A1 (zh) * 2019-12-27 2021-07-01 南京明德新药研发有限公司 苯并稠环类化合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
ITUB20161079A1 (it) 2016-02-25 2017-08-25 Hc Pharma Ag Procedimento per la preparazione di sofosbuvir
CN109311925B (zh) * 2016-05-12 2022-06-03 罗氏创新中心哥本哈根有限公司 立体限定的氧杂氮杂磷杂环戊烷亚磷酰胺单体与核苷或寡核苷酸的增强的偶联
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
ES2995514T3 (en) * 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
JP7694402B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694403B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694406B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694400B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694407B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694405B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機
JP7694401B2 (ja) * 2022-01-25 2025-06-18 株式会社三洋物産 遊技機

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3018302A (en) * 1956-12-20 1962-01-23 Asta Werke Ag Chem Fab Novel cyclic phosphoric acid ester amides, and the production thereof
US20070179114A1 (en) * 2004-02-13 2007-08-02 Metabasis Therapeutics, Inc. Novel 2'-C methyl nucleoside derivatives
US20110098251A1 (en) * 2009-10-26 2011-04-28 Warner Chilcott Company, Llc Bisphosphonate compounds
US20130310395A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1

Family Cites Families (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
BE633481A (https=) 1962-06-12
CA777769A (en) 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
US3328388A (en) 1964-09-02 1967-06-27 Merck & Co Inc Arabinofuranosyl pyrimidines and methods of preparing same
CH492738A (de) 1967-09-13 1970-06-30 Sandoz Ag Verfahren zur Herstellung von 2-(Bis-(2-chloräthyl)aminophenyl-4- -amino)-2H-1,3,2-oxazaphosphorin-tetrahydro-2-oxid
BE768925A (fr) 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
DE2752125A1 (de) 1977-11-22 1979-05-23 Max Planck Gesellschaft Neue phosphororganische ringverbindungen, ihre herstellung und verwendung
US4376165A (en) 1978-06-22 1983-03-08 Miles Laboratories, Inc. Method of preparing an enzyme-labeled ligand for use in specific binding assays and the labeled conjugate produced thereby
US4340668A (en) 1979-06-04 1982-07-20 Miles Laboratories, Inc. Heme-labeled specific binding assay
US4318982A (en) 1979-06-04 1982-03-09 Miles Laboratories, Inc. FMN-Labeled specific binding assay
US4255566A (en) 1980-02-19 1981-03-10 Miles Laboratories Flavin adenine dinucleotide derivatives and labeled conjugates prepared therefrom
US4447529A (en) 1981-07-06 1984-05-08 Miles Laboratories, Inc. Preparing homogeneous specific binding assay element to avoid premature reaction
DE3132221A1 (de) 1981-08-14 1983-05-19 Behringwerke Ag, 3550 Marburg Neue cyclophosphamid-derivate, verfahren zu ihrer herstellung und ihre verwendung
DE3133077A1 (de) 1981-08-21 1983-03-10 Henkel KGaA, 4000 Düsseldorf Neue cytostatisch wirksame epoxidgruppen tragende 1,3,2-oxazaphosphorin-verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung in pharmazeutischen zubereitungen
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4440740A (en) 1982-04-26 1984-04-03 Merck & Co., Inc. α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
US4464389A (en) 1982-10-20 1984-08-07 Sri International Esters of retinoic acid and pentaerythritol and monobenzal acetals thereof
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
US5047533A (en) 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
DE3569737D1 (en) 1984-03-01 1989-06-01 Asta Pharma Ag Salts of oxazaphosphorine derivatives
US4579849A (en) 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
FR2562543B1 (fr) 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
US4749694A (en) 1984-04-26 1988-06-07 Merck & Co., Inc. Novel lysine esters used as absorption
US4537772A (en) 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
US4898724A (en) 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
US4973579A (en) 1985-06-28 1990-11-27 Merck & Co., Inc. Enhancment of absorption of drugs from gastrointestinal tract using choline ester salts
US4729989A (en) 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4822773A (en) 1985-06-28 1989-04-18 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4847298A (en) 1985-08-16 1989-07-11 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4692441A (en) 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US4963525A (en) 1985-08-16 1990-10-16 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4963556A (en) 1985-08-16 1990-10-16 Merck & Co., Inc. Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US4731360A (en) 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US5258538A (en) 1985-08-26 1993-11-02 Applied Biosystems, Inc. 2,3-disubstituted-1,3,2-oxazaphosphacycloalkanes as nucleic acid linking agents
WO1987001284A1 (en) 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
US4879277A (en) 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
US5246937A (en) 1985-09-18 1993-09-21 Beecham Group P.L.C. Purine derivatives
DE3600289A1 (de) 1986-01-08 1987-07-09 Bayer Ag Cyclische malonylphosphonsaeurediamide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
JPH0615553B2 (ja) 1986-02-20 1994-03-02 日産化学工業株式会社 ジヒドロピリジン−５−ホスホンアミド酸類
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US4839466A (en) * 1986-04-11 1989-06-13 The Rockefeller University Insulin activity messengers
JPS62249996A (ja) 1986-04-23 1987-10-30 Asahi Chem Ind Co Ltd 新規なペンゾキサザホスホリン誘導体およびそれを有効成分とする殺虫剤組成物
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
DE3722043A1 (de) 1986-07-11 1988-01-14 Asta Werke Ag Chem Fab Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JPS6360929A (ja) 1986-08-29 1988-03-17 Yodogawa Seiyaku Kk 抗腫瘍剤
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
US5159067A (en) 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
US5077280A (en) 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
EP0338372A3 (en) 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
EP0353692B1 (en) 1988-08-02 1995-10-04 Nissan Chemical Industries Ltd. Drug effect-enhancing agent for antitumor drug
US4882142A (en) 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
JPH0377894A (ja) 1989-08-18 1991-04-03 Toray Ind Inc メチレンジホスホン酸化合物
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
CS387190A3 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
HU206883B (en) 1990-12-18 1993-01-28 Richter Gedeon Vegyeszet Process for producing new 15-nitro-2-beta-, 3-beta-dihydro- and 15-nitro-2-beta, 3-beta-, 6,7-tetrahydro-tabersonin derivatives and pharmaceutical compositions containing them
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
FR2681784B1 (fr) 1991-10-01 1995-06-09 Fabre Pierre Cosmetique Composition dermatologique et/ou cosmetologique contenant des retinouides et utilisation de nouveaux retinouides.
WO1993016388A1 (en) 1992-02-13 1993-08-19 The Uab Research Foundation Method of detecting and monitoring levels of 3'-amino-3'-deoxythymidine in body fluids and antibodies for same
GB2266527A (en) 1992-03-17 1993-11-03 Merck & Co Inc Substituted azetidinones useful in the treatment of leukemia
GB2266525A (en) 1992-03-17 1993-11-03 Merck & Co Inc Substituted cephalosporin sulfone compositions useful in the treatment of leukemia
GB9205917D0 (en) 1992-03-18 1992-04-29 Smithkline Beecham Plc Pharmaceuticals
AU4356693A (en) 1992-06-23 1994-01-24 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
US5532225A (en) 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
GB9301629D0 (en) 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
SK281309B6 (sk) 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
JP3526575B2 (ja) 1993-03-08 2004-05-17 エーザイ株式会社 ホスホン酸誘導体
ATE273700T1 (de) 1993-05-21 2004-09-15 Us Gov Health & Human Serv Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
US5514798A (en) 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
CA2637774C (en) 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
FR2709754B1 (fr) 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
AU691527B2 (en) 1993-09-17 1998-05-21 Gilead Sciences, Inc. Nucleotide analogs
US5437772A (en) 1993-11-01 1995-08-01 The Electrosynthesis Co., Inc. Portable lead detector
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5599686A (en) 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
CA2191980A1 (en) 1994-07-04 1996-01-18 Takashi Sohda Phosphonic acid compounds, their production and use
US5810856A (en) 1995-03-09 1998-09-22 Tveras; Rimvydas Wiping element for an oral hygiene device, window wiper, or the like
US5665713A (en) 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
EP0831852B1 (en) 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
US5665386A (en) 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5627164A (en) 1995-06-13 1997-05-06 Exxon Research And Engineering Company Pyrazolyl borates complexes-(LAW294)
WO1997003679A1 (en) 1995-07-17 1997-02-06 Cephalon, Inc. Phosphorous-containing cysteine and serine protease inhibitors
US5750493A (en) 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
AU1164597A (en) 1995-12-19 1997-07-14 Darwin Discovery Limited Ifosfamide, analogues thereof and their preparation
CA2195262C (en) 1996-01-18 2005-08-09 Masaru Ubasawa Phosphonate nucleotide compounds
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
JPH09241284A (ja) 1996-03-08 1997-09-16 Koji Yamashita 新規なオキシアザホスホリン誘導体
US6128582A (en) 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
RU2111970C1 (ru) 1996-06-25 1998-05-27 Иван Игоревич Федоров 3'-оксимино-2',3'-дидезоксинуклеозиды
GB9618634D0 (en) 1996-09-06 1996-10-16 Univ Southampton Anti cancer drugs
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
IL129126A0 (en) 1996-10-16 2000-02-17 Icn Pharmaceuticals Monocyclic l-nucleosides analogs and uses thereof
CZ141399A3 (cs) 1996-10-24 1999-07-14 Novartis Ag Substituované aminoalkanfosfonové kyseliny, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU717740B2 (en) 1996-11-19 2000-03-30 Icn Pharmaceuticals, Inc. Multivalent salts of pyridostigmine and related compounds
PL334197A1 (en) 1996-12-27 2000-02-14 Icn Pharmaceuticals Oligonucleotidic aptamers of high g content and methods of modulating immunilogical response
SE9700792L (sv) 1997-03-06 1998-02-23 Carlo Castro Ryggsmörjare för insmörjning av hudkräm på en människokropp
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
UA63956C2 (uk) 1997-06-30 2004-02-16 Ай-Сі-Ен Фармасьютикалз, Інк. Спосіб одержання нуклеозидів
US6130504A (en) 1997-07-11 2000-10-10 Sharp Kabushiki Kaisha Plasma addressing display device and method for producing the same
PT1256584E (pt) 1997-07-25 2004-12-31 Gilead Sciences Inc Processo para a preparacao de adefovir-dipivoxil
IL121413A (en) 1997-07-28 2000-10-31 Green Cloud Ltd Method for reducing the accumulation of precipitates and impurities on ultrasonic transducers
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6423695B1 (en) 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
WO1999036074A1 (en) 1998-01-15 1999-07-22 Icn Pharmaceuticals, Inc. Use of 8-cl-camp in prevention of restenosis of arterial walls
KR100719606B1 (ko) 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
WO1999045016A2 (en) 1998-03-06 1999-09-10 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
WO1999047549A1 (en) 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
DK1066247T3 (da) 1998-03-31 2007-04-02 Vertex Pharma Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
CA2333380A1 (en) 1998-05-26 1999-12-02 Icn Pharmaceuticals, Inc. Novel nucleosides having bicyclic sugar moiety
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
MXPA00012842A (es) 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
ES2255295T3 (es) 1998-08-10 2006-06-16 Idenix (Cayman) Limited 2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b.
ATE246197T1 (de) 1998-09-09 2003-08-15 Metabasis Therapeutics Inc Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
US6045638A (en) 1998-10-09 2000-04-04 Atlantic Research Corporation Monopropellant and propellant compositions including mono and polyaminoguanidine dinitrate
WO2000025780A1 (en) 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US6458773B1 (en) 1998-11-05 2002-10-01 Emory University Nucleoside with anti-hepatitis B virus activity
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
IL143569A0 (en) 1998-12-24 2002-04-21 Metabasis Therapeutics Inc A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US20020187945A1 (en) 1999-01-29 2002-12-12 Robert Tam Modulation of immune response by ribavirin
HUP0200260A3 (en) * 1999-03-05 2002-11-28 Metabasis Therapeutics Inc San Novel phosphorus-containing prodrugs, their preparation and their use
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
CA2377278C (en) 1999-06-25 2010-03-23 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of impdh
WO2001027114A1 (en) 1999-08-27 2001-04-19 Icn Pharmaceuticals, Inc. PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS
WO2001018013A1 (en) * 1999-09-08 2001-03-15 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CA2385747A1 (en) * 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
US6518253B1 (en) 1999-11-19 2003-02-11 Robert Tam Treatment of viral infections using the L-isomer of ribavirin
DE60038038T2 (de) 1999-12-03 2009-02-12 The Regents of The University of California at San Diego, La Jolla Phosphonatverbindungen
AU5076601A (en) 1999-12-13 2001-07-03 Icn Pharmaceuticals, Inc. Pulmonary delivery of ribavirin or levovirinTM for systemic and quasi-systemic treatment of disease
KR20030032908A (ko) 1999-12-23 2003-04-26 아이씨엔 파마슈티컬스, 인코포레이티드 Ｌ-누클레오시드, ｌ-누클레오티드 및 이들의 유사체에대한 조성물 및 방법
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
AU3653301A (en) 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6455508B1 (en) 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
AU3822701A (en) 2000-02-17 2001-08-27 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
WO2001077091A2 (en) 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
EP1964569A3 (en) 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
CN100490818C (zh) 2000-05-26 2009-05-27 诺瓦蒂斯有限公司 β-L-2′-脱氧核苷在制备用于治疗丁型肝炎病毒感染的药物中的用途
AU2001266610A1 (en) 2000-05-26 2001-12-11 Versatile Optical Networks, Inc. Wavelength locking system
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
GB0015627D0 (en) 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
MXPA03000277A (es) 2000-07-18 2004-04-05 Leo Pharma As Inhibidores de metaloproteinasa de matriz.
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CZ304734B6 (cs) 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
KR20030040416A (ko) 2000-08-22 2003-05-22 리버팜 인크. 간세포에 약물을 전달하는 방법 및 플라비비리대 감염을치료하는 방법
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
US6809101B2 (en) 2000-09-01 2004-10-26 Shionogi & Co., Ltd. Compounds having anti-hepatitis C virus effect
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
WO2002040021A2 (en) 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
US20040014696A1 (en) 2000-12-07 2004-01-22 Johnson Lau Specificity in treatment of diseases
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
JPWO2002051425A1 (ja) 2000-12-26 2004-04-22 三菱ウェルファーマ株式会社 Ｃ型肝炎治療剤
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2002083126A1 (en) 2001-04-11 2002-10-24 Idenix (Cayman) Limited Phenylindoles for the treatment of hiv
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
GB0119369D0 (en) 2001-08-08 2001-10-03 Bookham Technology Plc Optic system
GB2378524A (en) 2001-08-08 2003-02-12 Bookham Technology Plc Intergrated optic device
US20040077563A1 (en) 2001-08-21 2004-04-22 Johnson Lau Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
US20030232760A1 (en) 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP2005512516A (ja) 2001-09-24 2005-05-12 メルク　エンド　カムパニー　インコーポレーテッド スタチン薬物の組合せのスクリーニング方法および選択方法
JP2005536440A (ja) 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US20030072451A1 (en) 2001-10-16 2003-04-17 Pimentel Roberto J. Method and apparatus for securely transferring wireless data
JPWO2003034709A1 (ja) 2001-10-17 2005-02-10 ナルテック株式会社 伸長方法およびデータ処理装置
WO2003037908A1 (en) 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
AU2002353165A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
WO2003051881A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
WO2003051896A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Cytidine libraries and compounds synthesized by solid-phase combinatorial strategies
AU2002349905A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Nucleoside libraries and compounds by mcc combinatorial strategies on solid support
AU2002357876A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Nucleoside analog libraries and compounds
WO2003051898A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents
US7261704B2 (en) 2001-12-28 2007-08-28 Terumo Kabushiki Kaisha Syringe
WO2003062255A2 (en) 2002-01-17 2003-07-31 Ribapharm Inc. Sugar modified nucleosides as viral replication inhibitors
JP2005527499A (ja) 2002-02-13 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド ヌクレオシド化合物を用いてオルトポックスウイルスの複製を阻害する方法
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
EP1572945A2 (en) 2002-06-27 2005-09-14 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BR0312271A (pt) 2002-06-28 2007-11-06 Idenix Cayman Ltd compostos, composições e seus usos para o tratamento de infecções por flaviviridae
MXPA04012779A (es) 2002-06-28 2005-08-19 Idenix Cayman Ltd Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
AU2003279797B2 (en) 2002-09-30 2009-10-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
US7094768B2 (en) 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
JP5046219B2 (ja) 2002-10-31 2012-10-10 リガンド・ファーマシューティカルズ・インコーポレイテッド １，３−プロパン−１−アリールジオールの新規環状リン酸ジエステルおよびそのプロドラッグへの使用
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
TWI294882B (en) 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
EP1658302B1 (en) 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7144868B2 (en) 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP2007509939A (ja) 2003-10-27 2007-04-19 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染を治療するためのヌクレオシド化合物
TW200517106A (en) 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
US20060014740A1 (en) * 2003-11-18 2006-01-19 Miller Duane D Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
JPWO2005063222A1 (ja) 2003-12-26 2007-07-19 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
US7553825B2 (en) 2003-12-30 2009-06-30 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
WO2005123729A1 (en) 2004-06-08 2005-12-29 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
EP1781101A2 (en) 2004-07-29 2007-05-09 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
US7206468B2 (en) 2004-08-17 2007-04-17 Huang Hung-Chia Broad-band fiber-optic wave plates
WO2006136408A2 (en) 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing pure amorphous rosuvastatin calcium
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
US20070078111A1 (en) 2005-07-19 2007-04-05 Gabor Tigyi LPA2 receptor agonist inhibitors of CFTR
WO2007017117A1 (en) 2005-07-28 2007-02-15 Lek Pharmaceuticals D.D. Process for the synthesis of rosuvastatin calcium
US20090118223A1 (en) * 2005-08-12 2009-05-07 Erion Mark D Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
JP4954573B2 (ja) 2006-02-28 2012-06-20 オリンパス株式会社 内視鏡システム
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US7795291B2 (en) * 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
US8236820B2 (en) 2007-08-10 2012-08-07 Basil Rigas Anti-inflammatory compounds and uses thereof
US20100305060A1 (en) 2007-11-29 2010-12-02 Ligand Pharmaceuticals Incorporated Nucleoside Prodrugs and Uses Thereof
TW200936146A (en) 2007-11-29 2009-09-01 Metabasis Therapeutics Inc Antiviral nucleoside compounds
IT1391812B1 (it) 2008-07-29 2012-01-27 Maria Grazia Rimoli Profarmaco galattosilato del ketorolac ad uso analgesico e antinfiammatorio con migliori caratteristiche farmacocinetiche e profilo tossicologico del farmaco di partenza
WO2010042600A2 (en) 2008-10-08 2010-04-15 The Uab Research Foundation Photo-activatable therapeutic agents and methods of using
EP2351762B1 (en) 2008-10-20 2013-10-16 Kaneka Corporation NOVEL PYRIMIDINE DERIVATIVE AND METHOD FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR INTERMEDIATE
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
KR101091130B1 (ko) 2009-01-29 2011-12-09 (주)유케이케미팜 로슈바스타틴의 전구체 및 그의 제조 방법
GB0904100D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of rosuvastatin lactols as medicaments
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
CN102079726B (zh) 2009-11-27 2013-04-03 上海医药工业研究院 一类嘧啶类化合物及其中间体、制备方法和应用
JP2013514973A (ja) 2009-12-21 2013-05-02 メルク・シャープ・エンド・ドーム・コーポレイション チロシンキナーゼ阻害剤
WO2011160974A2 (en) 2010-06-21 2011-12-29 Nicox S.A. Statin derivatives
WO2012038785A1 (en) 2010-09-21 2012-03-29 Biocon Limited Polymorphs of rosuvastatin acetonide calcium ((3r,5s,6e)-7-[4-(4- fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimn)in-5- yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl) acetic acid calcium salt
US9095599B2 (en) * 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
CA2836579A1 (en) * 2011-05-19 2012-11-22 Rfs Pharma, Llc Purine monophosphate prodrugs for treatment of viral infections
CN103763928B (zh) 2011-06-06 2016-09-21 阿伯疗法责任有限公司 癌症化疗剂的酸不稳定的亲脂性前体药物
EP2780026B1 (en) * 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US20140142052A1 (en) 2012-05-17 2014-05-22 Normoxys, Inc. Phosphorylated polyols, pyrophosphates, and derivatives thereof having biological activity
WO2013187978A1 (en) * 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
WO2014043380A1 (en) 2012-09-14 2014-03-20 Ligand Pharmaceuticals Incorporated Novel nucleotide prodrug compounds and use
US9163055B2 (en) * 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
WO2015074328A1 (zh) 2013-11-25 2015-05-28 复旦大学 一种瑞舒伐他汀钠的制备方法
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
WO2016130417A1 (en) 2015-02-11 2016-08-18 Omthera Pharmaceuticals Inc Omega-3 fatty acid prodrug compounds and uses thereof
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3018302A (en) * 1956-12-20 1962-01-23 Asta Werke Ag Chem Fab Novel cyclic phosphoric acid ester amides, and the production thereof
US20070179114A1 (en) * 2004-02-13 2007-08-02 Metabasis Therapeutics, Inc. Novel 2'-C methyl nucleoside derivatives
US20110098251A1 (en) * 2009-10-26 2011-04-28 Warner Chilcott Company, Llc Bisphosphonate compounds
US20130310395A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129827A1 (zh) * 2019-12-27 2021-07-01 南京明德新药研发有限公司 苯并稠环类化合物
CN114846001A (zh) * 2019-12-27 2022-08-02 南京明德新药研发有限公司 苯并稠环类化合物
CN114846001B (zh) * 2019-12-27 2024-01-23 南京明德新药研发有限公司 苯并稠环类化合物

Also Published As

Publication number Publication date
AU2015217221A1 (en) 2016-08-11
CN114404427A (zh) 2022-04-29
JP2022009127A (ja) 2022-01-14
US10449210B2 (en) 2019-10-22
EP3105238A1 (en) 2016-12-21
CA2937548C (en) 2022-10-25
CA2937548A1 (en) 2015-08-20
AU2020200786A1 (en) 2020-02-20
US20190388452A1 (en) 2019-12-26
EP3623364A1 (en) 2020-03-18
EP3105238A4 (en) 2017-11-08
US11278559B2 (en) 2022-03-22
WO2015123352A1 (en) 2015-08-20
JP2020073466A (ja) 2020-05-14
JP2017512183A (ja) 2017-05-18
AU2021225211A1 (en) 2021-09-30
WO2015123352A9 (en) 2016-09-09
US20170056429A1 (en) 2017-03-02
AU2015217221A9 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
US11278559B2 (en) Prodrug compounds and their uses
TWI789479B (zh) 胺基磷酸酯(膦醯胺酯)縮醛以及磷酸酯(膦酸酯)縮醛化合物
US10150788B2 (en) Prodrug compounds and uses thereof
TW202313066A (zh) 非天然構型之核苷酸前藥化合物
CA2944805C (en) Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof
HK40072666A (en) Prodrug compounds and their uses
HK40026405A (en) Prodrug compounds and their uses
KR102959095B1 (ko) 사이클릭 디옥시리보뉴클레오티드 화합물
RU2796403C2 (ru) Фосфор(n)амидатацетальные и фосф(он)атацетальные соединения
HK1231883A1 (en) Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof
HK1231883B (zh) 菲罗啉膦酸类衍生物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161026

RJ01 Rejection of invention patent application after publication